Along this view, Leslie and colleagues have recently reported that antagonizing CXCR2 in neutrophils sensitizes mice harbouring NASH-HCC to anti-PD-1 immunotherapy reducing the tumor burden and increasing the survival rate [66]. This evidence concerns the gene CXCR2 and metabolic dysfunction-associated steatohepatitis.